New Jersey Cannabis in 2026: More Sales, Lower Prices and More Competition

New Jersey’s cannabis market is still expanding, although statewide sales records now coexist with lower prices, more retail locations and declining medical enrollment as adult-use access expands. Growth remains strong, but individual operators are finding it more difficult to capture that growth profitably.

The state recorded $1.16 billion in combined cannabis sales in 2025, up from $1.08 billion in 2024. Adult-use sales increased nearly 12% to $1.12 billion and accounted for almost all of that growth. By April 2026, monthly sales had reached nearly $109 million, approximately 20% above April 2025 and the highest total reported by the New Jersey Cannabis Regulatory Commission.

According to the NJ-CRC’s May 2026 market update, transactions increased 74% between January 2023 and April 2026, while sales rose 52% and prices declined a striking 48%. Consumers are buying more frequently, but each purchase is generating less revenue on average.

Lower prices can attract new customers and encourage existing consumers to buy more often. The financial result depends on whether that additional volume produces enough gross profit to cover inventory, payroll, taxes and other operating costs. Naturally, market growth does not automatically translate into profit. Many New Jersey businesses may be participating in an expanding market while their margins narrow.

Growth Is Being Distributed Across More Businesses

Another important feature of the market is that growth is being distributed across more businesses than last year. New Jersey had more than 190 dispensaries at the end of 2024 and more than 270 one year later. By May 2026, the Commission reported that more than 300 dispensaries were operating across all 21 counties.

More businesses remain in the licensing pipeline. The NJ-CRC’s latest published totals, updated after its September 9 public meeting, list 967 conditional retail awards, 285 conditional-to-annual conversions and 182 annual retail licenses. These categories overlap to some extent as applicants progress through the system, so they cannot be added together as a count of future stores. They nevertheless indicate that retail competition will continue to expand.

The pressure varies considerably by location because municipalities control which business classes may operate, how many they allow and where those businesses can open. A retailer may face several established competitors within a small trade area while consumers elsewhere still have limited access.

Retailers should therefore estimate how many customers they can reach, how frequently they return, what they place in each basket and how much discounting is required to retain them. Those conditions can change again when nearby licenses become operational.

Lower Prices Are Changing the Performance Equation

The average adult-use flower price fell from $8.86 per gram in April 2025 to $6.80 in April 2026, a decline of approximately 23%, according to NJ-CRC Acting Executive Director Christopher Riggs.

The recently launched High Times Trans-High Market Quotations tracker shows the same downward direction, although at a higher recorded price. In July 2026, a 3.5-gram New Jersey eighth averaged $32.23, or $9.21 per gram. That represented a 0.6% monthly decline, while the three-, six- and twelve-month changes stood at -0.5%, -6.5% and -11.7%, respectively. Across the recorded period, price compression was persistent.

In a methodological note, we should clarify that the figures measure different portions of the market. The NJ-CRC’s $6.80 figure is a statewide average per gram across adult-use flower sales, including larger package sizes that typically sell for less per gram. HTMQ’s $9.21 figure is a weighted retail average specifically for 3.5-gram eighths, calculated from Hoodie Analytics’ participating dispensary data. Therefore, they are not strictly comparable in absolute numbers, but they help us understand the trend, which is consistent across both sources.

Flower still accounted for just over 42% of the market in the NJ-CRC’s 2025 review, followed by vape cartridges at 26.4%, edibles at 11% and pre-rolls at 10.7%. For an individual retailer, those statewide shares provide context but cannot determine the right product mix. Local demand, available brands, customer demographics and nearby competition can produce a very different sales profile.

Falling prices place more weight on product-level economics. Operators need to know which brands generate repeat purchases, which products move only when discounted, how long inventory remains on the shelf and how much gross profit remains after promotions. Strong unit sales can give an incomplete impression of performance when much of that volume comes from products with weak margins.

The Medical Market Continues to Contract

New Jersey recorded $46.2 million in medicinal cannabis sales in 2025, down from $83.9 million in 2024. Registered patient enrollment also fell from 52,877 at the end of 2025 to 42,984 by September 15, 2026.

Some patients may be shifting into the adult-use market as access expands and maintaining a medical registration becomes less useful. Riggs attributed part of the decline in medical sales to patients purchasing through adult-use dispensaries, which are now available across all 21 counties.

Other factors may also be contributing. During the Commission’s 2025 patient consultations, participants raised concerns about price, product availability, limited medical-specific offerings and insufficient information about dosing, strains, and product selection.

Businesses serving both markets should track medical and adult-use activity separately. Combining them can obscure changes in inventory demand, staffing requirements, and patient services, while the distinction may also carry federal tax consequences. Under the April 2026 federal rule, marijuana covered by a qualifying state medical license was placed in Schedule III, while adult-use marijuana generally remained in Schedule I.

This could produce a two-tier system in which qualifying medical operations receive relief from Section 280E, giving some operators an incentive to expand that side of the business.

A higher share of medical sales alone does not establish eligibility, however, making separate records and specialized tax advice essential.

A Stronger Local Network

Verdant’s participation in NECANN New Jersey took place within this increasingly competitive environment. The September 18–19 convention brought retailers, cultivators, manufacturers, brands and service providers together around the New Jersey market. Jennifer Makris represented Verdant on a panel titled “Building the Cannabis Back Office: Banking, Cash & Operational Strategy”, addressing several of the systems operators need as lower prices and greater competition place more pressure on cash flow.

In her remarks at NECANN, Makris also acknowledged the support of Rachel Wright, founder and CEO of Verdant Strategies, recalling Wright’s words: “Jennifer, you speak my language. You speak financial services.” She credited Wright’s belief in her with helping her continue her work in the industry, adding: “So thank you to Rachel Wright for giving me that opportunity.”

The event also coincided with Verdant’s new partnership with the New Jersey Cannabis Chamber of Commerce. Known as NJC3, the Chamber brings together plant-touching operators, ancillary businesses and other participants in the state’s cannabis industry. It also hosted the official NECANN welcome reception on September 17, with Verano as the main sponsor. For Verdant’s team, the reception offered an opportunity to reconnect with familiar faces and meet new industry contacts ahead of the convention.

The Chamber’s membership program includes in-person events, virtual meetings, referrals, educational workshops, webinars, training, marketing opportunities and business-development support. Its programming has addressed technology, compliance, inventory systems and operational efficiency, while upcoming sessions cover corporate responsibility, cultivation, laboratory testing, packaging and product integrity.

According to Verdant’s team on site, NECANN New Jersey was well attended despite competing industry events. Signage near the convention check-in area increased Verdant’s visibility, while a booth positioned between Redman and Jim Belushi helped draw strong traffic. The team reported productive conversations, meaningful engagements and new business opportunities in New Jersey, one of Verdant’s target markets.

These services respond to all stages of business development. A new licensee may need introductions to cannabis-friendly banks, insurers, accountants, technology providers and vendors. An operating dispensary may be looking for stronger cash controls, inventory systems or expansion planning. More established businesses can use policy engagement and industry meetings to compare regulatory costs and communicate recurring problems.

Through its partnership with NJC3, Verdant contributes accounting, tax, cash-management and fractional CFO experience to that network. The relationship also provides a setting for developing financial education around the problems that become harder to manage as a market matures, including price compression, inventory exposure, cash planning and store-level profitability.

A More Local View of Growth

New Jersey still has room to expand as additional licensees become operational and regulated access reaches more municipalities. The same figures demonstrating that growth also show lower prices, increased competition, and continued contraction in the medical market.

Verdant’s partnership with NJC3 and its participation in NECANN deepen its connection to the New Jersey cannabis ecosystem and help us better understand the operating environment, thus allowing us to provide top service to our clients in that state. Operators evaluating their performance or preparing for another stage of growth can learn more about Verdant Strategies’ accounting, tax, and advisory services and request a discovery meeting here.